Back to Directory Chris Stainsby Email chris.m.stainsby@viivhealthcare.com Institution ViiV Healthcare Request an Update Affiliated Studies IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum DAIDS Number 38953 Research Area Therapeutics Study Status Pending
IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum DAIDS Number 38953 Research Area Therapeutics Study Status Pending